Literature DB >> 13710650

Pharmacological agents in experimental hemorrhagic shock. A controlled comparison of treatment with hydralazine, hydrocortisone, and levarterenol (1-norepinephrine).

R W HAKSTIAN, L G HAMPSON, F N GURD.   

Abstract

Entities:  

Keywords:  HYDRALAZINE/pharmacology; HYDROCORTISONE/pharmacology; NOREPINEPHRINE/pharmacology; SHOCK/experimental

Mesh：

Substances：

Year:  1961        PMID： 13710650     DOI： 10.1001/archsurg.1961.01300150009002

Source DB:  PubMed          Journal:  Arch Surg        ISSN： 0004-0010


× No keyword cloud information.
  7 in total

1.  CONTROLLED HYPOTENSION IN THE MANAGEMENT OF SEVERE HEMORRHAGE.

Authors:  R W HOPKINS; R FRATIANNE; I PENN; G SABGA; F A SIMEONE
Journal:  Ann Surg       Date:  1964-10       Impact factor: 12.969

2.  Small intestinal blood flow.

Authors:  E C TEXTER
Journal:  Am J Dig Dis       Date:  1963-07

3.  Anaesthetic and surgical considerations in partial hepatectomy.

Authors:  J I Davies; A Kaplan
Journal:  Can Anaesth Soc J       Date:  1968-05

4.  Combined adrenergic blockade in experimental hemorrhagic hypotension.

Authors:  G Zierott; E Pappova; P Lundsgaard-Hansen
Journal:  Pflugers Arch       Date:  1969-06-24       Impact factor: 3.657

5.  Experimental pneumococcal and staphylococcal sepsis: effects of hydrocortisone and phenoxybenzamine upon mortality rates.

Authors:  H G Robson; L E Cluff
Journal:  J Clin Invest       Date:  1966-09       Impact factor: 14.808

6.  Preclinical studies of NOS inhibitor T1059 vasopressor activity on the models of acute hemorrhagic shock in rats and dogs.

Authors:  Marina Filimonova; Ljudmila Shevchenko; Victoria Makarchuk; Alina Saburova; Petr Shegay; Andrey Kaprin; Sergey Ivanov; Alexander Filimonov
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

7.  Does vasopressor therapy have an indication in hemorrhagic shock?

Authors:  François Beloncle; Ferhat Meziani; Nicolas Lerolle; Peter Radermacher; Pierre Asfar
Journal:  Ann Intensive Care       Date:  2013-05-22       Impact factor: 6.925
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.